Nami Therapeutics Corp (’Nami’) is a startup company based in Storrs, CT and currently in the Technology Incubation Program at the University of Connecticut. Nami is developing specifically designed nanoparticles for the targeted delivery of therapeutic agents, including radio-therapeutics, to tumors. Nami (which mean ‘nano’ in Mandarin) is using technologies licensed from the University of Connecticut and the University of North Carolina. The Nami team is comprised of Xiuling Lu and Michael Jay, academics with over 50 years of collective experience in the drug delivery field, Ruobing Xia, who has 20+ years of experience in big pharma managing multi-million dollar product launches, and David Worthen, an experienced scientist and entrepreneur with product development, regulatory affairs, and management experience in both industry and academia. Nami aims to advance it nanotechnology-based products to the clinical trial stage by demonstrating the efficacy of its products in preclinical models, and by completing IND enabling activities such as manufacturing process development (CMC) and safety/toxicity assessments.